New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona, Verona, Italy; 3Allergy & Respiratory Di...
Guardado en:
Autores principales: | Caminati M, Bagnasco D, Vaia R, Senna G |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/94f3d5e54f2e44f0bbf5750e6f077a31 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: John Davison, et al.
Publicado: (2021) -
Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia
por: Kawabata H, et al.
Publicado: (2021) -
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar P
Publicado: (2017) -
Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
por: Angelantonio Maglio, et al.
Publicado: (2021) -
Characterizing Inflammatory Cell Asthma Associated Phenotypes in Dental Health Workers Using Cytokine Profiling
por: Tanusha Singh, et al.
Publicado: (2021)